ADGRE2: A Promising Immunotherapeutic Target in Acute Myeloid Leukemia and Chronic Myelomonocytic Leukemia.

Neiss J, Hemetsberger L, Schaefer C, Rijksen M, Schwab A, Zebisch A, Reinisch A, Sill H, Heine A, Wölfler A

Open source

DOI
10.1002/cam4.72497
Published
2026 Nov
Container
Cancer medicine
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1002/cam4.72497,
  title = {ADGRE2: A Promising Immunotherapeutic Target in Acute Myeloid Leukemia and Chronic Myelomonocytic Leukemia.},
  author = {Neiss J and Hemetsberger L and Schaefer C and Rijksen M and Schwab A and Zebisch A and Reinisch A and Sill H and Heine A and Wölfler A},
  year = {2026},
  journal = {Cancer medicine},
  doi = {10.1002/cam4.72497},
  url = {https://doi.org/10.1002/cam4.72497}
}

RIS

TY  - JOUR
TI  - ADGRE2: A Promising Immunotherapeutic Target in Acute Myeloid Leukemia and Chronic Myelomonocytic Leukemia.
AU  - Neiss J
AU  - Hemetsberger L
AU  - Schaefer C
AU  - Rijksen M
AU  - Schwab A
AU  - Zebisch A
AU  - Reinisch A
AU  - Sill H
AU  - Heine A
AU  - Wölfler A
PY  - 2026
JO  - Cancer medicine
DO  - 10.1002/cam4.72497
UR  - https://doi.org/10.1002/cam4.72497
ER  - 

APA

J, N., L, H., C, S., M, R., A, S., A, Z., A, R., H, S., A, H., & A, W. (2026). ADGRE2: A Promising Immunotherapeutic Target in Acute Myeloid Leukemia and Chronic Myelomonocytic Leukemia.. Cancer medicine. https://doi.org/10.1002/cam4.72497

Source records